The Effect Of Meditation On Quality Of Life In Women With Breast Cancer And Other Gynecological Cancers
This trial is active, not recruiting.
|Conditions||breast cancers, gynecologic cancer|
|Treatment||mindfulness based meditation program|
|Sponsor||Weill Medical College of Cornell University|
|Start date||May 2003|
|End date||March 2010|
|Trial size||200 participants|
|Trial identifier||NCT00248911, 0209005792|
Women with breast cancer and other gynecologic cancers often suffer significant distress and disability from their disease. A practice of meditation-based stress reduction and cognitive-affective-behavioral learning may help women with these conditions decrease their suffering and improve their quality of life.
|Endpoint classification||efficacy study|
|Intervention model||single group assignment|
|Primary purpose||supportive care|
Quality of life will be assessed by within patient differences in the FACT-G (General Functional Assessment of Cancer Treatment Scale), as well as with the disease specific subscales at baseline and at 12 months.
time frame: Subjects will complete questionnaires at baseline and closeout. Patients will participate in the meditation program weekly for 20 weeks.
Female participants at least 18 years old.
- All women with stage I-III breast or other gynecologic cancer who have received treatment within the preceding year will be eligible for inclusion in the study.
- Patients who refuse to participate will be excluded
- Patients with Metastatic cancer are excluded.
|Official title||The Effect Of Meditation On Quality Of Life In Women With Breast Cancer And Other Gynecological Cancers:Avon Program for Meditation and Healing|
|Principal investigator||Mary E Charlson, MD|
|Description||The objective of this project in women recently treated for breast or other gynecologic cancer is to determine whether an intervention program consisting of group and individual instruction in a meditation-based practice of stress-reduction and cognitive-affective-behavioral learning has the potential for reducing disabling distress and improving quality of life in a population vulnerable to the progression or recurrence of disease. Quality of life will be assessed at 12 months.|
Call for more information